Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies

Journal of Affective Disorders

Volumn 215, Issue , 2017, Pages 205-212

  Earley, Willie ^a   Durgam, Suresh ^a   Lu, Kaifeng ^a   Debelle, Marc ^b   Laszlovszky, István ^b   Vieta, Eduard ^c   Yatham, Lakshmi N ^d  

^a Allergan plc   (United States)

^b GEDEON RICHTER LTD   (Hungary)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARIPRAZINE; GLUCOSE; PLACEBO; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SOMNOLENCE; SUICIDAL IDEATION; WEIGHT CHANGE; WEIGHT GAIN; AKATHISIA, DRUG-INDUCED; BIPOLAR DISORDER; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85016036459     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.03.032     Document Type: Article

References (37)

1. APA, Diagnostic and Statistical Manual of Mental Disorders,. fourth ed. (text revision), 2000, American Psychiatric Association, Washington DC.
2. Barnes, T.R., A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989), 672–676.
3. Birkenaes, A.B., Opjordsmoen, S., Brunborg, C., Engh, J.A., Jonsdottir, H., Ringen, P.A., Simonsen, C., Vaskinn, A., Birkeland, K.I., Friis, S., Sundet, K., Andreassen, O.A., The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J. Clin. Psychiatry 68 (2007), 917–923.
4. Calabrese, J.R., Keck, P.E. Jr., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Nemeth, G., Durgam, S., Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry 76 (2015), 284–292.
5. Cha, D.S., McIntyre, R.S., Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin. Pharm. 13 (2012), 1587–1598.
6. Cho, D.I., Zheng, M., Kim, K.M., Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors. Arch. Pharm. Res. 33 (2010), 1521–1538.
7. Cruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J.M., Valenti, M., Vieta, E., Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int. J. Neuropsychopharmacol. 13 (2010), 5–14.
8. Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Nemeth, G., Laszlovszky, I., An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr. Res. 152 (2014), 450–457.
9. Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Nemeth, G., Laszlovszky, I., The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 17 (2015), 63–75.
10. Durgam, S., Cutler, A.J., Lu, K., Migliore, R., Ruth, A., Laszlovszky, I., Nemeth, G., Meltzer, H.Y., Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J. Clin. Psychiatry 76 (2015), e1574–e1582.
11. Durgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Németh, G., Vieta, E., Calabrese, J.R., Yatham, L.N., An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am. J. Psychiatry 173 (2016), 271–281.
12. Fountoulakis, K.N., An update of evidence-based treatment of bipolar depression: where do we stand?. Curr. Opin. Psychiatry 23 (2010), 19–24.
13. Grande, I., Berk, M., Birmaher, B., Vieta, E., Bipolar disorder. Lancet 387 (2016), 1561–1572.
14. Gross, G., Drescher, K., The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb. Exp. Pharmacol., 2012, 167–210.
15. Guy, W., The Abnormal Movement Scale, ECDEU Assessment Manual for Psychopharmacology. 1976, National Institutes of Mental Health, Rockvill, MD, 218–222.
16. Guy, W., The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. 1976, National Institute of Mental Health, Rockville, MD, 218–222.
17. Gyertyan, I., Saghy, K., Laszy, J., Elekes, O., Kedves, R., Gemesi, L.I., Pasztor, G., Zajer-Balazs, M., Kapas, M., Agai Csongor, E., Domany, G., Kiss, B., Szombathelyi, Z., Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiede. Arch. Pharm. 378 (2008), 529–539.
18. Kane, J.M., Fleischhacker, W.W., Hansen, L., Perlis, R., Pikalov, A. 3rd, Assuncao-Talbott, S., Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 70 (2009), 627–643.
19. Kane, J.M., Zukin, S., Wang, Y., Lu, K., Ruth, A., Nagy, K., Laszlovszky, I., Durgam, S., Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J. Clin. Psychopharmacol. 35 (2015), 367–373.
20. Kane, J.M., Barnes, T.R., Correll, C.U., Sachs, G., Buckley, P., Eudicone, J., McQuade, R., Tran, Q.V., Pikalov, A. 3rd, Assuncao-Talbott, S., Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J. Psychopharmacol. 24 (2010), 1019–1029.
21. Kiss, B., Laszlovszky, I., Horvath, A., Nemethy, Z., Schmidt, E., Bugovics, G., Fazekas, K., Gyertyan, I., Agai-Csongor, E., Domany, G., Szombathelyi, Z., Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: i. neurochemical characterisation of RG-15. Naunyn Schmiede. Arch. Pharmacol. 378 (2008), 515–528.
22. Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H.Y., Roth, B.L., H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003), 519–526.
23. Leboyer, M., Kupfer, D.J., Bipolar disorder: new perspectives in health care and prevention. J. Clin. Psychiatry 71 (2010), 1689–1695.
24. Leung, J.Y., Barr, A.M., Procyshyn, R.M., Honer, W.G., Pang, C.C., Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther. 135 (2012), 113–122.
25. Liauw, S.S., McIntyre, R.S., Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin. Pharm. 11 (2010), 2827–2837.
26. Montgomery, S.A., Åsberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
27. Nakamura, T., Kubota, T., Iwakaji, A., Imada, M., Kapas, M., Morio, Y., Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des. Dev. Therapy 10 (2016), 327–338.
28. Pacchiarotti, I., Murru, A., Kotzalidis, G.D., Bonnin, C.M., Mazzarini, L., Colom, F., Vieta, E., Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur. Neuropsychopharmacol. 25 (2015), 1045–1059.
29. Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S., Mann, J.J., The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168 (2011), 1266–1277.
30. Reynolds, G.P., Histamine and antipsychotic drug-induced weight gain. J. Psychopharmacol. 26 (2012), 1608–1609.
31. Richelson, E., New antipsychotic drugs: how do their receptor-binding profiles compare?. J. Clin. Psychiatry 71 (2010), 1243–1244.
32. Sachs, G.S., Greenberg, W.M., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Nemeth, G., Durgam, S., Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J. Affect. Disord. 174 (2015), 296–302.
33. Simpson, G.M., Angus, J.W., A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212 (1970), 11–19.
34. Vieta, E., Rosa, A.R., Evolving trends in the long-term treatment of bipolar disorder. World J. Biol. Psychiatry 8 (2007), 4–11.
35. Vieta, E., Durgam, S., Lu, K., Ruth, A., Debelle, M., Zukin, S., Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur. Neuropsychopharmacol. 25 (2015), 1882–1891.
36. Yildiz, A., Vieta, E., Leucht, S., Baldessarini, R.J., Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36 (2011), 375–389.
37. Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978), 429–435.